Evidence map›Paper›PMID 41588006›Full record

ArticleNature communications2026

Targeting mGlyR with nanobodies for depression.

Thibaut Laboute, Stefano Zucca, Omar K Sial, Mansi Sharma, Gloria Brunori, Shikha Singh, K V Nageswar, Haiyong Peng, Christoph Rader, Jérôme Aj Becker and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Thibaut LabouteUniversité de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, Tours, France.ORCID http://orcid.org/0000-0003-0870-1891
Stefano Zucca *Department of Neuroscience, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL, USA.ORCID http://orcid.org/0000-0002-8781-3295
Omar K Sial *Department of Neuroscience, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL, USA.
Mansi Sharma *Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, Uttar Pradesh, India.ORCID http://orcid.org/0009-0008-2358-1844
Gloria Brunori *Department of Physiology and Biophysics, University of Miami Miller School of Medicine, Miami, FL, USA.
Shikha SinghDepartment of Biological Sciences, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0003-0266-4241
K V NageswarDepartment of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, Uttar Pradesh, India.
Haiyong PengDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL, USA.ORCID http://orcid.org/0000-0003-0312-1337
Christoph RaderDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL, USA.ORCID http://orcid.org/0000-0001-9955-3454
Jérôme Aj BeckerUniversité de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, Tours, France.ORCID http://orcid.org/0000-0002-0039-0067
Julie Le MerrerUniversité de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, Tours, France.ORCID http://orcid.org/0000-0002-8670-4273
Appu K SinghDepartment of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, Uttar Pradesh, India. singhappu@iitk.ac.in.ORCID http://orcid.org/0000-0002-2685-4018
Kirill A MartemyanovDepartment of Physiology and Biophysics, University of Miami Miller School of Medicine, Miami, FL, USA. kmartemyanov@miami.edu.

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH105482
6 · The paper itself

Abstract

Development of therapies for neuropsychiatric conditions is one of the greatest challenges of modern medicine. Common limitations of traditional small molecule drugs include poor efficacy, off-target side effects and difficult druggability of many targets. In this study, we report a different approach deploying small engineered single domain antibodies, known as nanobodies, for the treatment of depression, a prevalent neuropsychiatric condition. We develop highly selective nanobodies for a recently discovered glycine receptor mGlyR crucially linked to pathophysiology of depression. Using a mouse model of stress-induced depression, we show that non-invasive intranasal delivery of nanobody produces rapid and lasting anti-depressant effect. We solve an atomic structure of mGlyR bound to nanobody and use a variety of cell-based approaches to reveal the mechanism of mGlyR modulation and its impact on neural circuitry. These findings support development of biologics for the treatment of intractable brain disorders.

Indexed as

Antidepressive AgentsDepressionReceptors, GlycineSingle-Domain AntibodiesAdministration, IntranasalAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLAntidepressive AgentsReceptors, GlycineSingle-Domain Antibodies

Identifiers

PMID41588006
PMCPMC12834959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.